- Home
- NNE vs CSTL Comparison
NNE vs CSTL Comparison
Compare NNE & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNE
- CSTL
- Stock Information
- Founded
- NNE 2022
- CSTL 2007
- Country
- NNE United States
- CSTL United States
- Employees
- NNE N/A
- CSTL N/A
- Industry
- NNE
- CSTL Medical Specialities
- Sector
- NNE
- CSTL Health Care
- Exchange
- NNE NYSE
- CSTL Nasdaq
- Market Cap
- NNE 718.5M
- CSTL 832.4M
- IPO Year
- NNE 2024
- CSTL 2019
- Fundamental
- Price
- NNE $19.56
- CSTL $34.67
- Analyst Decision
- NNE Strong Buy
- CSTL Strong Buy
- Analyst Count
- NNE 2
- CSTL 6
- Target Price
- NNE $44.50
- CSTL $34.83
- AVG Volume (30 Days)
- NNE 6.1M
- CSTL 390.9K
- Earning Date
- NNE 11-14-2024
- CSTL 11-04-2024
- Dividend Yield
- NNE N/A
- CSTL N/A
- EPS Growth
- NNE N/A
- CSTL N/A
- EPS
- NNE N/A
- CSTL N/A
- Revenue
- NNE N/A
- CSTL $287,589,000.00
- Revenue This Year
- NNE N/A
- CSTL $37.67
- Revenue Next Year
- NNE N/A
- CSTL N/A
- P/E Ratio
- NNE N/A
- CSTL N/A
- Revenue Growth
- NNE N/A
- CSTL 71.67
- 52 Week Low
- NNE $3.25
- CSTL $16.14
- 52 Week High
- NNE $37.51
- CSTL $34.73
- Technical
- Relative Strength Index (RSI)
- NNE N/A
- CSTL 66.28
- Support Level
- NNE N/A
- CSTL $31.19
- Resistance Level
- NNE N/A
- CSTL $33.30
- Average True Range (ATR)
- NNE 0.00
- CSTL 1.44
- MACD
- NNE 0.00
- CSTL 0.18
- Stochastic Oscillator
- NNE 0.00
- CSTL 98.31
About NNE NANO NUCLEAR ENERGY INC
Nano Nuclear Energy Inc is an early-stage nuclear energy company developing smaller, cheaper, and safer advanced portable clean energy solutions. It is focused on four business lines as part of development: Micro Nuclear Reactor Business is developing the next-generation nuclear microreactors, in particular ZEUS, a solid core battery reactor, and ODIN, a low-pressure salt coolant reactor. Fuel Fabrication Business, Fuel Transportation Business and Nuclear Consultation Services.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.